EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Response‐adapted consolidation therapy strategy for patients with metastatic high‐risk neuroblastoma: Results of the SMC NB‐2014 study

Eun Seop Seo iD, Ji Won Lee iD, Hee Won Cho iD, Hee Young Ju iD, Young Seok Cho iD, Sanghoon Lee iD, Seung Hwan Moon iD, Keon Hee Yoo iD, Do Hoon Lim iD, Ki Woong Sung iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31173 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Eun Seop Seo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Neuroblastoma, Consolidation Chemotherapy, 3-Iodobenzylguanidine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health and Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tandem high‐dose chemotherapy and autologous stem cell transplantation (HDCT/auto‐SCT) and incorporation of 131 I‐metaiodobenzylguanidine ( 131 I‐MIBG) treatment have shown positive outcomes in high‐risk neuroblastoma. However, more optimized treatment strategies are still needed. Procedure The NB‐2014 study was a nonrandomized, prospective trial that examined survival outcomes in metastatic high‐risk neuroblastoma patients using response‐adapted consolidation therapy. We used post‐induction residual 123 I‐MIBG status at metastatic sites as a treatment response marker. Patients achieving complete resolution of MIBG uptake at metastatic sites underwent a reduced first HDCT/auto‐SCT with a 20% dose reduction in HDCT. After the first HDCT/auto‐SCT, patients with remaining MIBG uptake received dose‐escalated (18 mCi/kg) 131 I‐MIBG treatment. In contrast, those with complete resolution of MIBG at metastatic sites received a standard dose (12 mCi/kg) of 131 I‐MIBG. We compared survival and toxicity outcomes with a historical control group from the NB‐2009.

Results

Of 65 patients treated, 63% achieved complete resolution of MIBG uptake at metastatic sites following induction chemotherapy, while 29% of patients still had MIBG uptake at metastatic sites after the first HDCT/auto‐SCT. The 3‐year event‐free survival (EFS) and overall survival (OS) rates were 68.2% ± 6.0% and 86.5% ± 4.5%, respectively. Compared to NB‐2009, EFS was similar ( p = .855); however, NB‐2014 had a higher OS ( p = .031), a lower cumulative incidence of treatment‐related mortality ( p = .036), and fewer acute and late toxicities.

Conclusions

Our results suggest that response‐adaptive consolidation therapy based on chemotherapy response at metastatic sites facilitates better treatment tailoring, and appears promising for patients with metastatic high‐risk neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaConsolidation Chemotherapy3-IodobenzylguanidineHumansFemaleMaleChild, PreschoolInfantChildProspective StudiesSurvival RateAntineoplastic Combined Chemotherapy ProtocolsAdolescentFollow-Up StudiesTransplantation, AutologousPrognosisHematopoietic Stem Cell TransplantationRadiopharmaceuticals

Stichwörter der Autor:innen

MIBGhigh riskhigh‐dose chemohterapyneuroblastomaresponse‐adapted

Substanzen

3-IodobenzylguanidineRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
  • Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Eun Seop Seo, Ji Won Lee, Hee Won Cho, Hee Young Ju, Young Seok Cho, Sanghoon Lee, Seung Hwan Moon, Keon Hee Yoo, Do Hoon Lim, Ki Woong Sung

Förderung

  • Ministry of Health and Welfare, Republic of Korea

Zitieren

APA

Seo, E. S., Lee, J. W., Cho, H. W., Ju, H. Y., Cho, Y. S., Lee, S., Moon, S. H., Yoo, K. H., Lim, D. H., & Sung, K. W. (2024). Response‐adapted consolidation therapy strategy for patients with metastatic high‐risk neuroblastoma: Results of the SMC NB‐2014 study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31173

Vancouver

Seo ES, Lee JW, Cho HW, Ju HY, Cho YS, Lee S, et al. Response‐adapted consolidation therapy strategy for patients with metastatic high‐risk neuroblastoma: Results of the SMC NB‐2014 study. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31173

BibTeX
@article{Seo2024,
  author = {Seo, Eun Seop and Lee, Ji Won and Cho, Hee Won and Ju, Hee Young and Cho, Young Seok and Lee, Sanghoon and Moon, Seung Hwan and Yoo, Keon Hee and Lim, Do Hoon and Sung, Ki Woong},
  title = {Response‐adapted consolidation therapy strategy for patients with metastatic high‐risk neuroblastoma: Results of the SMC NB‐2014 study},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31173}
}
Kostenlos starten →